Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06099769 · ClinicalTrials.gov registry record · Phase 2
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
A Phase 2 study of Metastatic Breast Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 201
- Enrollment target
- 12
- Study locations
NCT06099769 is a Phase 2 study of Metastatic Breast Cancer that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 201 participants, roughly in line with the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target. The trial reports 12 study locations across 7 states.
The verdict
NCT06099769, a Phase 2 study of Metastatic Breast Cancer, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 201 participants
- Enrollment target
- 12
- Study locations
Study Summary
The researchers are doing this study to find out if the study drug, enzalutamide, alone or combined with the study drug, mifepristone, is effective in treating advanced or metastatic androgen receptor-positive (AR+) triple negative breast cancer (TNBC) or estrogen receptor-low breast cancer (ER-low BC), and whether these study treatments work as well as standard chemotherapy with carboplatin, paclitaxel, capecitabine, or eribulin.
Conditions Studied
Interventions
- DRUG Enzalutamide
- DRUG Mifepristone
- DRUG TPC
Study Locations (12)
New York
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Alabama
- University of Alabama at Birmingham - Birmingham
California
- University of California San Francisco (Data collection only) - San Francisco
Illinois
- University of Chicago Medical Center - Chicago
Massachusetts
- Dana Farber Cancer Institute (Data Collection Only) - Boston
North Carolina
- University of North Carolina - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 201 participants |
| Start Date | 2023-10-18 |
| Est. Completion | 2027-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06099769
The ClinicalTrials.gov registry entry for NCT06099769 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 201 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Enzalutamide is the first listed.
NCT06099769 reports 12 study locations spanning 7 distinct geographic areas - top geographies include New York, New Jersey, Alabama.
Frequently Asked Questions
What is clinical trial NCT06099769 about?
NCT06099769 is a clinical study titled "A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer". The researchers are doing this study to find out if the study drug, enzalutamide, alone or combined with the study drug, mifepristone, is effective in treating advanced or metastatic androgen receptor-positive (AR+) triple negative breast cancer (TNBC) or estrogen receptor-low breast cancer (ER-low ...
What is the current status of trial NCT06099769?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 201 participants. The study started on 2023-10-18. Estimated completion is 2027-10.
What conditions does trial NCT06099769 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer.
What interventions are being tested in trial NCT06099769?
The interventions under investigation include: Enzalutamide (DRUG), Mifepristone (DRUG), TPC (DRUG).
Who is sponsoring clinical trial NCT06099769?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06099769 being conducted?
This trial has 12 study locations across Alabama, California, Illinois, Massachusetts, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu
RECRUITING · Phase 2
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
RECRUITING · Phase 2
-
A Study of Surgery and Radiotherapy in People With Breast Cancer
RECRUITING · Phase 2
-
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
RECRUITING · Phase 2
-
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.